Relapse remains a leading cause of death after allogeneic hematopoietic
cell transplantation (HCT) for patients with high-risk
leukemias. The potentially beneficial donor T cell-mediated graft-versus-
leukemia (GVL) effect is often mitigated by concurrent
graft-versus-host disease (GVHD). Providing T cells that can selectively target
Wilms tumor antigen 1 (WT1), a
transcription factor overexpressed in
leukemias that contributes to the malignant phenotype, represents an opportunity to promote antileukemic activity without inducing GVHD.
HLA-A*0201-restricted WT1-specific donor-derived CD8 cytotoxic T cell (CTL) clones were administered after HCT to 11 relapsed or high-risk
leukemia patients without evidence of on-target toxicity. The last four treated patients received CTL clones generated with exposure to
interleukin-21 (IL-21) to prolong in vivo CTL survival, because
IL-21 can limit terminal differentiation of
antigen-specific T cells generated in vitro. Transferred cells exhibited direct evidence of antileukemic activity in two patients: a transient response in one patient with advanced progressive disease and the induction of a prolonged remission in a patient with
minimal residual disease (MRD). Additionally, three treated patients at high risk for relapse after HCT survive without
leukemia relapse, GVHD, or additional antileukemic treatment. CTLs generated in the presence of
IL-21, which were transferred in these latter three patients and the patient with MRD, all remained detectable long-term and maintained or acquired in vivo phenotypic and functional characteristics associated with long-lived memory CD8 T cells. This study supports expanding efforts to immunologically target WT1 and provides insights into the requirements necessary to establish potent persistent T cell responses.